The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
December 2nd 2024
Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.
November 27th 2024
November 26th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Pegloticase Injection Plus Methotrexate Significantly Increases Response Rate in Patients with Gout
Results were based on the phase 4 MIRROR trial, which analyzed differences in treatment response for concomitant therapy compared with placebo in adults with uncontrolled gout.
Patients with Autoimmune Disease at Greater Complications Risk Following Heart Attack
Investigators believe that coronary intervention, intensified medical therapy, and an aggressive risk factor optimization approach should be available to patients with rheumatic disease presenting with myocardial infarction whenever possible.
Q&A: Determinants of Work, Social Participation in Patients With Psoriatic Arthritis
September 13th 2022In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.
Litifilimab Superior to Placebo in Patients with Cutaneous Lupus Erythematosus
“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”
Autoimmune Disease Increases Risk of Developing Cardiovascular Disease
Although investigations have been performed on the association between inflammatory conditions and cardiovascular events, the effect of different conditions on cardiovascular diseases has not been analyzed on a large scale.